Which has better earnings and valuation, PODD or DXCM?

DexCom has higher revenue and earnings than Insulet. Insulet is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insulet $3.05B 3.00 $247.10M $5.35 24.67 DexCom $4.97B 6.31 $836.30M $2.53 32.82

Is PODD or DXCM more profitable?

DexCom has a net margin of 20.12% compared to Insulet's net margin of 12.29%. DexCom's return on equity of 35.94% beat Insulet's return on equity. Company Net Margins Return on Equity Return on Assets Insulet 12.29% 29.29% 13.31% DexCom 20.12% 35.94% 14.75%

Does the media favor PODD or DXCM?

In the previous week, Insulet had 1 more articles in the media than DexCom. MarketBeat recorded 15 mentions for Insulet and 14 mentions for DexCom. Insulet's average media sentiment score of 1.12 beat DexCom's score of 0.89 indicating that Insulet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive DexCom 7 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, PODD or RMD?

ResMed has higher revenue and earnings than Insulet. ResMed is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insulet $3.05B 3.00 $247.10M $5.35 24.67 ResMed $5.65B 5.57 $1.52B $10.43 20.93

Is PODD or RMD more profitable?

ResMed has a net margin of 26.94% compared to Insulet's net margin of 12.29%. Insulet's return on equity of 29.29% beat ResMed's return on equity. Company Net Margins Return on Equity Return on Assets Insulet 12.29% 29.29% 13.31% ResMed 26.94% 25.58% 18.89%

Does the media prefer PODD or RMD?

In the previous week, Insulet had 1 more articles in the media than ResMed. MarketBeat recorded 15 mentions for Insulet and 14 mentions for ResMed. Insulet's average media sentiment score of 1.12 beat ResMed's score of 1.11 indicating that Insulet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive ResMed 12 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PODD or GEHC?

In the previous week, GE HealthCare Technologies had 2 more articles in the media than Insulet. MarketBeat recorded 17 mentions for GE HealthCare Technologies and 15 mentions for Insulet. GE HealthCare Technologies' average media sentiment score of 1.40 beat Insulet's score of 1.12 indicating that GE HealthCare Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive GE HealthCare Technologies 13 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate PHG or PODD?

Insulet has a consensus target price of $195.40, suggesting a potential upside of 48.08%. Given Insulet's stronger consensus rating and higher possible upside, analysts plainly believe Insulet is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Koninklijke Philips 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Insulet 2 Sell rating(s) 11 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.44

Does the media prefer PHG or PODD?

In the previous week, Insulet had 14 more articles in the media than Koninklijke Philips. MarketBeat recorded 15 mentions for Insulet and 1 mentions for Koninklijke Philips. Insulet's average media sentiment score of 1.12 beat Koninklijke Philips' score of 1.00 indicating that Insulet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Koninklijke Philips 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insulet 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, PODD or STE?

STERIS has higher revenue and earnings than Insulet. Insulet is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insulet $3.05B 3.00 $247.10M $5.35 24.67 STERIS $6.04B 3.41 $782.30M $8.18 25.81

Is PODD or STE more profitable?

STERIS has a net margin of 13.34% compared to Insulet's net margin of 12.29%. Insulet's return on equity of 29.29% beat STERIS's return on equity. Company Net Margins Return on Equity Return on Assets Insulet 12.29% 29.29% 13.31% STERIS 13.34% 14.34% 9.66%

Does the media prefer PODD or STE?

In the previous week, Insulet had 12 more articles in the media than STERIS. MarketBeat recorded 15 mentions for Insulet and 3 mentions for STERIS. Insulet's average media sentiment score of 1.12 beat STERIS's score of 1.06 indicating that Insulet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive STERIS 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Insulet (PODD) Competitors

$131.96 -2.72 (-2.02%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$132.50 +0.54 (+0.41%)

As of 09/11/2026 07:30 PM Eastern

Compare

PODD vs. DXCM, RMD, GEHC, PHG, and STE

Should you buy Insulet stock or one of its competitors? Insulet's main competitors and comparable companies include DexCom (DXCM), ResMed (RMD), GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), and STERIS (STE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Insulet compare to DexCom?

Insulet (NASDAQ:PODD) and DexCom (NASDAQ:DXCM) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Insulet has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, DexCom has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market.

DexCom has a net margin of 20.12% compared to Insulet's net margin of 12.29%. DexCom's return on equity of 35.94% beat Insulet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	12.29%	29.29%	13.31%
DexCom	20.12%	35.94%	14.75%

97.8% of DexCom shares are owned by institutional investors. 0.4% of Insulet shares are owned by company insiders. Comparatively, 0.3% of DexCom shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Insulet had 1 more articles in the media than DexCom. MarketBeat recorded 15 mentions for Insulet and 14 mentions for DexCom. Insulet's average media sentiment score of 1.12 beat DexCom's score of 0.89 indicating that Insulet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
DexCom	7 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Insulet presently has a consensus target price of $195.40, indicating a potential upside of 48.08%. DexCom has a consensus target price of $88.71, indicating a potential upside of 6.84%. Given Insulet's higher possible upside, analysts clearly believe Insulet is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	2 Sell rating(s)	11 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.44
DexCom	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.92

DexCom has higher revenue and earnings than Insulet. Insulet is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$3.05B	3.00	$247.10M	$5.35	24.67
DexCom	$4.97B	6.31	$836.30M	$2.53	32.82

Summary

DexCom beats Insulet on 12 of the 17 factors compared between the two stocks.

How does Insulet compare to ResMed?

Insulet (NASDAQ:PODD) and ResMed (NYSE:RMD) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

ResMed has higher revenue and earnings than Insulet. ResMed is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$3.05B	3.00	$247.10M	$5.35	24.67
ResMed	$5.65B	5.57	$1.52B	$10.43	20.93

Insulet has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, ResMed has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

55.0% of ResMed shares are owned by institutional investors. 0.4% of Insulet shares are owned by company insiders. Comparatively, 0.7% of ResMed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ResMed has a net margin of 26.94% compared to Insulet's net margin of 12.29%. Insulet's return on equity of 29.29% beat ResMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	12.29%	29.29%	13.31%
ResMed	26.94%	25.58%	18.89%

Insulet presently has a consensus target price of $195.40, suggesting a potential upside of 48.08%. ResMed has a consensus target price of $240.31, suggesting a potential upside of 10.09%. Given Insulet's stronger consensus rating and higher possible upside, analysts clearly believe Insulet is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	2 Sell rating(s)	11 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.44
ResMed	0 Sell rating(s)	10 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38

In the previous week, Insulet had 1 more articles in the media than ResMed. MarketBeat recorded 15 mentions for Insulet and 14 mentions for ResMed. Insulet's average media sentiment score of 1.12 beat ResMed's score of 1.11 indicating that Insulet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ResMed	12 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Insulet and ResMed tied by winning 8 of the 16 factors compared between the two stocks.

How does Insulet compare to GE HealthCare Technologies?

Insulet (NASDAQ:PODD) and GE HealthCare Technologies (NASDAQ:GEHC) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

Insulet presently has a consensus target price of $195.40, suggesting a potential upside of 48.08%. GE HealthCare Technologies has a consensus target price of $77.73, suggesting a potential upside of 21.58%. Given Insulet's higher probable upside, equities research analysts plainly believe Insulet is more favorable than GE HealthCare Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	2 Sell rating(s)	11 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.44
GE HealthCare Technologies	0 Sell rating(s)	11 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.48

GE HealthCare Technologies has higher revenue and earnings than Insulet. GE HealthCare Technologies is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$3.05B	3.00	$247.10M	$5.35	24.67
GE HealthCare Technologies	$21.27B	1.36	$2.08B	$4.36	14.66

Insulet has a net margin of 12.29% compared to GE HealthCare Technologies' net margin of 9.33%. Insulet's return on equity of 29.29% beat GE HealthCare Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	12.29%	29.29%	13.31%
GE HealthCare Technologies	9.33%	20.12%	5.74%

Insulet has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, GE HealthCare Technologies has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

82.1% of GE HealthCare Technologies shares are owned by institutional investors. 0.4% of Insulet shares are owned by company insiders. Comparatively, 0.4% of GE HealthCare Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, GE HealthCare Technologies had 2 more articles in the media than Insulet. MarketBeat recorded 17 mentions for GE HealthCare Technologies and 15 mentions for Insulet. GE HealthCare Technologies' average media sentiment score of 1.40 beat Insulet's score of 1.12 indicating that GE HealthCare Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
GE HealthCare Technologies	13 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Insulet beats GE HealthCare Technologies on 9 of the 15 factors compared between the two stocks.

How does Insulet compare to Koninklijke Philips?

Koninklijke Philips (NYSE:PHG) and Insulet (NASDAQ:PODD) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

Koninklijke Philips has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Insulet has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

Insulet has a net margin of 12.29% compared to Koninklijke Philips' net margin of 6.30%. Insulet's return on equity of 29.29% beat Koninklijke Philips' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Koninklijke Philips	6.30%	14.38%	5.96%
Insulet	12.29%	29.29%	13.31%

In the previous week, Insulet had 14 more articles in the media than Koninklijke Philips. MarketBeat recorded 15 mentions for Insulet and 1 mentions for Koninklijke Philips. Insulet's average media sentiment score of 1.12 beat Koninklijke Philips' score of 1.00 indicating that Insulet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Koninklijke Philips	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Koninklijke Philips has higher revenue and earnings than Insulet. Koninklijke Philips is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Koninklijke Philips	$17.67B	1.37	$1.01B	$1.36	18.10
Insulet	$3.05B	3.00	$247.10M	$5.35	24.67

13.7% of Koninklijke Philips shares are held by institutional investors. 0.4% of Insulet shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Insulet has a consensus target price of $195.40, suggesting a potential upside of 48.08%. Given Insulet's stronger consensus rating and higher possible upside, analysts plainly believe Insulet is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Koninklijke Philips	0 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Insulet	2 Sell rating(s)	11 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.44

Summary

Insulet beats Koninklijke Philips on 13 of the 16 factors compared between the two stocks.

How does Insulet compare to STERIS?

Insulet (NASDAQ:PODD) and STERIS (NYSE:STE) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Insulet has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, STERIS has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

94.7% of STERIS shares are held by institutional investors. 0.4% of Insulet shares are held by company insiders. Comparatively, 1.1% of STERIS shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

STERIS has a net margin of 13.34% compared to Insulet's net margin of 12.29%. Insulet's return on equity of 29.29% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	12.29%	29.29%	13.31%
STERIS	13.34%	14.34%	9.66%

Insulet currently has a consensus price target of $195.40, suggesting a potential upside of 48.08%. STERIS has a consensus price target of $271.33, suggesting a potential upside of 28.53%. Given Insulet's higher probable upside, research analysts plainly believe Insulet is more favorable than STERIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	2 Sell rating(s)	11 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.44
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Insulet had 12 more articles in the media than STERIS. MarketBeat recorded 15 mentions for Insulet and 3 mentions for STERIS. Insulet's average media sentiment score of 1.12 beat STERIS's score of 1.06 indicating that Insulet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
STERIS	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

STERIS has higher revenue and earnings than Insulet. Insulet is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$3.05B	3.00	$247.10M	$5.35	24.67
STERIS	$6.04B	3.41	$782.30M	$8.18	25.81

Summary

STERIS beats Insulet on 9 of the 16 factors compared between the two stocks.

Get Insulet News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PODD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PODD vs. The Competition

Export

Metric	Insulet	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.34B	$5.38B	$7.13B	$12.72B
Dividend Yield	N/A	1.79%	2.56%	11.15%
P/E Ratio	24.67	25.09	275.24	25.29
Price / Sales	3.00	82.90	655.99	98.94
Price / Cash	21.30	32.53	77.04	51.44
Price / Book	6.13	5.97	10.33	6.20
Net Income	$247.10M	$150.75M	$3.50B	$358.50M
7 Day Performance	-10.52%	-2.83%	-3.32%	-2.35%
1 Month Performance	-9.03%	-3.09%	-0.41%	-2.77%
1 Year Performance	-61.39%	9.34%	19.21%	7.63%

Insulet Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PODD Insulet	4.2314 of 5 stars	$131.96 -2.0%	$195.40 +48.1%	-61.0%	$9.34B	$3.05B	24.67	5,400	Positive News
DXCM DexCom	3.4517 of 5 stars	$87.90 flat	$88.71 +0.9%	+9.3%	$33.17B	$4.66B	34.74	11,000
RMD ResMed	4.1468 of 5 stars	$228.25 0.0%	$240.31 +5.3%	-20.6%	$32.94B	$5.65B	21.88	11,370	Positive News Analyst Forecast Insider Trade
GEHC GE HealthCare Technologies	4.4655 of 5 stars	$68.86 flat	$77.73 +12.9%	-18.0%	$31.10B	$20.63B	15.79	54,000	Positive News
PHG Koninklijke Philips	2.9986 of 5 stars	$25.89 flat	N/A	-14.0%	$25.45B	$20.17B	19.08	65,340	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PODD) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Insulet (PODD) Competitors